Logo Image

Shorts

In this video, Arturo Loaiza-Bonilla, MD, MSEd, FACP, discussed best use cases for artificial intelligence (AI) in oncology.
0:52
Outlining Best Use Cases For AI in Oncology
6 months ago
by
Arturo Loaiza-Bonilla, MD, MSEd, FACP
Arturo Loaiza-Bonilla, MD, MSEd, FACP, discussed advances in the application of AI to oncology that he believes will have the potential to transform practice for patients undergoing treatment for cancer.
0:52
AI May Function Like “Connective Tissue” in the Clinical Oncology Continuum
6 months ago
by
Arturo Loaiza-Bonilla, MD, MSEd, FACP
Brandon Mancini, MD, MBA, FACRO, introduces the RadOnc on the Run podcast, a program dedicated to discussing critical advances and considerations in radiation oncology care and research.
1:03
Introducing RadOnc on the Run: CancerNetwork’s New Podcast Initiative
6 months ago
by
Brandon Mancini, MD, MBA, FACRO
Soumen Das, MS, FACS, MRCS, FRCS, outlined 3 pillars for breast cancer the GBCI, a wing of the WHO outlined among other key performance indices (KPIs) for breast cancer care.
0:49
Aligning With the WHO GBCI: 3 Pillars for Breast Cancer Treatment
6 months ago
by
Soumen Das, MBBS, MS, FACS
Soumen Das, MS, FACS, MRCS, FRCS, discussed the integration of a breast cancer reporting and data system (BCRADS) for low- and middle-income countries to help improve outcomes in low resource settings (LRS).
0:46
Decentralizing Breast Oncology Care in LMIDs Through Clinical Reporting/Data System
6 months ago
by
Soumen Das, MBBS, MS, FACS
Surbhi Sidana, MD, associate professor of medicine and lead of the Myeloma CAR-T/Immunotherapy Program at Stanford University in California, discussed the importance of funding for hematologic oncology research in an interview with CancerNetwork®.
0:40
NIH Funding May Be Instrumental to Developing Multiple Myeloma Research
6 months ago
by
Surbhi Sidana, MD
Surbhi Sidana, MD, discussed what implications the approval of teclistamab plus daratumumab among patients with relapsed/refractory multiple myeloma would have on practice for this disease.
1:04
Daratumumab/Teclistamab Multiple Myeloma Approval Could Expand Treatment Options
6 months ago
by
Surbhi Sidana, MD
Nathan Goodyear, MD, touched upon research which might suggest that malignant cancer cells may be able to be transformed back to normal functioning ones.
1:24
Could Malignant Cancer Cells Be Transformed Back to Normal Functioning Ones?
6 months ago
by
Nathan Goodyear, MD
Nathan Goodyear, MD, discussed the “restoration” of the patient-doctor relationship in integrative oncology and oncology as a whole brought about by patient demands for a more collaborative relationship.
1:16
Restoring the Patient-Doctor Relationship Through Collaboration in Integrative Oncology
6 months ago
by
Nathan Goodyear, MD
Ash Tewari, MBBS, MCh, FRCS, discussed the impact that a mobile prostate cancer testing unit has had on the local community.
0:52
Unplanned Mobile Unit Testing Identified Early-Stage Prostate Cancer
6 months ago
by
Ash Tewari, MD, MBBS, MCh, FRCS
In this video, Tewari highlighted developments in nerve-sparing prostate cancer procedures, with a particular emphasis on one that is aimed at preserving erectile function following surgery.
0:41
Recovering Sexual Function Through Nerve-Sparing GU Procedures
6 months ago
by
Ash Tewari, MD, MBBS, MCh, FRCS
For this video, Janjigian highlighted the unifying impact of the MATTERHORN trial, which established perioperative immunotherapy among this patient group regardless of location.
1:27
Unifying Perioperative Immunotherapy Globally in Gastric Cancer Treatment
6 months ago
by
Yelena Y. Janjigian, MD
Janjigian discussed the role of pathologic complete response rate as an early indicator for cure among patients with gastric cancer, particularly in the absence of long-term survival data.
0:56
Pathologic CR Rates May Provide Early Indicator of Cure in Gastric Cancers
6 months ago
by
Yelena Y. Janjigian, MD
Janjigian touched upon key design elements of the MATTERHORN trial, which sought to assess the safety and efficacy of the FLOT-based combination among patients with gastric cancer globally.
0:56
Treating Gastric Cancer With “Modern” FLOT Backbone Regardless of PD-L1 Status
6 months ago
by
Yelena Y. Janjigian, MD
In an interview with CancerNetwork®, Nathan Goodyear, MD, discussed the creation of "hot" tumor microenvironment through integrative oncology strategies.
1:19
Creating an Immune “Hot” Tumor Microenvironment Through Integrative Oncology
7 months ago
by
Nathan Goodyear, MD
James R. Berenson, MD, outlined the benefits of the text-based monitoring of symptoms and quality of life (mQOL) platform on patient-reported outcomes (PROs) in clinical practice at the 2025 American Society of Hematology (ASH) Annual Meeting and Exposition.
0:51
Spotlighting a 3-Minute mQOL Questionnaire for PROs in Hematology
7 months ago
by
James R. Berenson, MD, FACP
Krina K. Patel, MD, MSc, discussed the efficiency of the mechanism of action for anito-cel, which uses a smaller protein to increase the frequency of CAR transductions in patients undergoing treatment for relapsed/refractory multiple myeloma.
0:46
Maximizing CAR T-cell Efficiency in Multiple Myeloma Through the D-Domain
7 months ago
by
Krina K. Patel, MD, MSc
Hannah Goulart, MD, a hematology oncology fellow at the MD Anderson Cancer Center, explained that patients with Ph-positive B-ALL may experience an improvement in QOL with an immunotherapy-based backbone vs a chemotherapy-based backbone.
0:37
How Removing Intensive Chemotherapy May Improve QOL in Ph+ B-ALL
7 months ago
by
Hannah Goulart, MD
Charles S. Kamen, PhD, MPH, suggests that clinicians should anticipate a greater sensitivity to cues of rejection among patients that are sexual or gender minorities, which would prompt them to make a greater effort to include a patient’s support people in decision-making processes.
1:13
Highlighting Decision-Making Inclusion for LGBTQ+ Loved Ones/Caregivers
7 months ago
by
Charles S. Kamen, PhD, MPH
Charles S. Kamen, PhD, MPH, discussed the prevalence of minority stress, which could emerge in an anticipatory fashion, due to systemic prejudices impacting these patients.
1:30
Addressing the Burden of Disclosure for LGBTQ+ Patients in Oncology Care
7 months ago
by
Charles S. Kamen, PhD, MPH
Charles S. Kamen, PhD, MPH, discussed the prevalence of LGBTQ+ individuals in oncology care, as well as navigating difficulties associated with delivering patient-centric care to them.
1:19
Practice With Cultural Humility: Treating LGBTQ+ Patients with Cancer
8 months ago
by
Charles S. Kamen, PhD, MPH
Daniel Peters, MD, discussed 3 main pillars he uses to guide practice when treating patients with acute myeloid leukemia (AML); patient health, treatment goals, and molecular testing (genomics).
0:45
Guiding AML Treatment Stategy: Three Pillars For Clinicians
8 months ago
by
Daniel Peters, MD
Cary Gross, MD, discussed results from a study he coauthored regarding quality of care outcomes among patients treated with cancer during incarceration or within the year following release. Specifically, he discussed a need for the re-engagement of patients with cancer who were recently released from incarceration in the health care system and programs such as the Transitions Programs, which aim to fulfill that need.
0:53
Engaging Patients With Cancer Into Health Care Systems After Incarceration
8 months ago
by
Cary Gross, MD
Thomas Marron, MD, discussed a presentation he gave at the Chemotherapy Foundation Symposium (CFS) titled, "Stage I-III Is Not What It Used to Be".
0:51
Immune System Training: Explicating Perioperative Immunotherapy Use
8 months ago
by
Thomas Marron, MD, PhD
Rona Yaeger, MD, discussed key takeaways from her presentation titled, “Targeting BRAF, KRAS, and HER2 in GI Tumors” in an interview at the 43rd Annual Chemotherapy Foundation Symposium (CFS) in New York, NY.
0:41
Testing For Mutational Status Might Improve Colorectal Cancer Survival
8 months ago
by
Rona Yaeger, MD
Michael Barish, PhD, discussed the application of a scorpion venom-derived chlorotoxin in treating 4 patients with glioblastoma in an interview with CancerNetwork.
1:01
Exploring The Applicability of Scorpion Venom in Glioblastoma Treatment
8 months ago
by
Michael Barish, PhD
Toru Kondo, PhD, discussed his presentation titled, "Evaluating EVA1-ADC as a Novel Therapeutic Strategy for Eliminating Glioblastoma-Initiating Cells," that he gave at World ADC
0:54
EVA1-Targeting ADCs May Reduce AEs vs Anti-CD133 Agents in Glioblastoma
8 months ago
by
Toru Kondo, PhD
ADCs May Be Emerging As Preferred Backbone in HER2+/HR+ Breast Settings
0:44
ADCs May Be Emerging As Preferred Backbone in HER2+/HR+ Breast Settings
8 months ago
by
Aditya Bardia, MD, MPH, FASCO
Patients with medullary thyroid carcinoma or the MEN type 2 genetic disorder should not start GLP-1 agents for risk of insulin secretion and severe hypoglycemia.
0:37
When Should Patients with NETs Be Advised Not To Take GLP-1 Agents?
8 months ago
by
Joseph Dillon, MB, BCh, BAO
Micheal C. Soulen, MD, discussed his presentation of the phase 2 CapTemY90 trial assessing the combination of radioembolization and chemotherapy in patients with liver-dominant NETs at the 2025 North American Neuroendocrine Tumor Symposium.
0:37
Y90/Radiosensitizing Chemotherapy Regimen Feasible in Liver-Dominnat NETs
9 months ago
by
Michael C. Soulen, MD